228 related articles for article (PubMed ID: 16257613)
21. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
22. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
Winkler UH; Krämer R; Kwee B; Schindler AE
Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
[TBL] [Abstract][Full Text] [Related]
23. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
[TBL] [Abstract][Full Text] [Related]
24. Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women.
Rios DR; Rodrigues ET; Cardoso AP; Montes MB; Franceschini SA; Toloi MR
Nutrition; 2008 Feb; 24(2):120-6. PubMed ID: 18065202
[TBL] [Abstract][Full Text] [Related]
25. Effect of four oral contraceptives on hemostatic parameters.
Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H
Contraception; 2004 Aug; 70(2):97-106. PubMed ID: 15288212
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the central effects of different progestins used in hormone replacement therapy.
Cagnacci A; Arangino S; Baldassari F; Alessandrini C; Landi S; Volpe A
Maturitas; 2004 Aug; 48(4):456-62. PubMed ID: 15283939
[TBL] [Abstract][Full Text] [Related]
27. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
[TBL] [Abstract][Full Text] [Related]
28. Influence of hormone replacement therapy (17 beta-OH estradiol and medroxyprogesterone acetate) on plasma concentration of prothrombin fragment F1+2 and thrombin-antithrombin III complex in postmenopausal woman.
Ciepłluch R; Czestochowska E
Acta Haematol Pol; 1996; 27(1):21-5. PubMed ID: 8629439
[TBL] [Abstract][Full Text] [Related]
29. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
30. Circulating concentrations of hemostatic factors and two "steroid sensitive proteins" during oral hormone replacement therapy in women with coronary heart disease.
Pripp U; Schenck-Gustafsson K; Landgren BM; Carlström K
Scand J Clin Lab Invest; 2004; 64(7):659-65. PubMed ID: 15513323
[TBL] [Abstract][Full Text] [Related]
31. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
[TBL] [Abstract][Full Text] [Related]
32. Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease.
Lindoff C; Petersson F; Samsioe G; Astedt B
Int J Fertil Menopausal Stud; 1994; 39(3):133-9. PubMed ID: 7920748
[TBL] [Abstract][Full Text] [Related]
33. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
[TBL] [Abstract][Full Text] [Related]
34. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
[TBL] [Abstract][Full Text] [Related]
35. The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies.
Acs N; Vajo Z; Miklos Z; Siklosi G; Paulin F; Felicetta JV; Székåcs B
Gynecol Endocrinol; 2002 Aug; 16(4):335-46. PubMed ID: 12396563
[TBL] [Abstract][Full Text] [Related]
36. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey.
Lowe GD; Upton MN; Rumley A; McConnachie A; O'Reilly DS; Watt GC
Thromb Haemost; 2001 Aug; 86(2):550-6. PubMed ID: 11522002
[TBL] [Abstract][Full Text] [Related]
37. [Changes in the blood coagulation and fibrinolysis system in the course of normal pregnancy].
Justus B; Siegert G; Tiebel O
Zentralbl Gynakol; 1992; 114(4):165-70. PubMed ID: 1621453
[TBL] [Abstract][Full Text] [Related]
38. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy.
Nozaki M; Ogata R; Koera K; Hashimoto K; Nakano H
Climacteric; 1999 Jun; 2(2):124-30. PubMed ID: 11910665
[TBL] [Abstract][Full Text] [Related]
39. Effect of the cessation of long-term hormone replacement therapy on plasma plasminogen activator inhibitor-1 and fibrinogen.
Kalela A; Jokela H; Lehtimäki T; Uppa H; Kunnas T; Teisala K; Punnonen R; Nikkari ST
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):217-20. PubMed ID: 16337074
[TBL] [Abstract][Full Text] [Related]
40. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease.
Seljeflot I; Arnesen H; Hofstad AE; Os I
Thromb Haemost; 2000 Jun; 83(6):944-8. PubMed ID: 10896253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
